
|Slideshows|August 11, 2017
FDA Drug and Biologic Approvals for Neurology: 2017 Midyear Review
Author(s)Natalie Timoshin
Seven new drugs were approved for treatment of neurological disorders, including Parkinson disease, multiple sclerosis, and amyotrophic lateral sclerosis.
Advertisement
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission
2
FDA Approves Intrathecal Version of Zolgensma, Ozempic Falls Short in EVOKE Trials, Asundexian Meets End Point in Stroke Prevention Trial
3
Exploring New Therapeutic Targets for Neurodegenerative Diseases: Robert G. Kalb, MD
4
Early Phase 3 Data Highlight Convenience and Feasibility of Self-Administered Alzheimer Agent Remternetug
5


































